参考图片
Expression of IL-10 by stimulated CD4+ rat splenocytes. Purified splenic CD4+ cells from 6 month old Lewis rats were stimulated with plate-bound anti-CD3 (25 µg/ml final concentration; G4.18, Cat. No. 554829) and soluble anti-rat CD28 (2 µg/ml final concentration; clone JJ319, Cat. No. 554993) for 2 days in culture together with rat IL- 2 (10 ng/ml final concentration; Cat. No. 555106) and rat IL-4 (10 ng/ml final concentration; Cat. No 555107), followed by a 3 day incubation with only rat IL-2 and rat IL-4. This was followed by a 6 hour stimulation with PMA (1 ng/ml final concentration; Sigma, Cat. #P-8139) and Ionomycin (250 ng/ml final concentration; Sigma, Cat. #I-0634) in the presence of BD GolgiStop ™ (2 µM final concentration Cat. No. 554724). The cells were then fixed, permeabilized, and subsequently stained with 0.06 µg of PE Mouse anti rat IL-10 antibody (PE-A5-4, Cat. No. 555088; Left panel) by using Pharmingen's staining protocol. To demonstrate specificity of staining, the binding of the PE-A5-4 antibody was blocked by preincubation of the PE- conjugated antibody with recombinant rat IL-10 (0.25 µg, Cat. No. 555113; Second panel), and by preincubation of the fixed/permeabilized cells with the unlabeled A5-4 antibody (10 µg; Right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (Center panel) and unlabeled antibody blocking (Right panel) specificity controls.
Expression of IL-10 by stimulated CD4+ rat splenocytes. Purified splenic CD4+ cells from 6 month old Lewis rats were stimulated with plate-bound anti-CD3 (25 µg/ml final concentration; G4.18, Cat. No. 554829) and soluble anti-rat CD28 (2 µg/ml final concentration; clone JJ319, Cat. No. 554993) for 2 days in culture together with rat IL- 2 (10 ng/ml final concentration; Cat. No. 555106) and rat IL-4 (10 ng/ml final concentration; Cat. No 555107), followed by a 3 day incubation with only rat IL-2 and rat IL-4. This was followed by a 6 hour stimulation with PMA (1 ng/ml final concentration; Sigma, Cat. #P-8139) and Ionomycin (250 ng/ml final concentration; Sigma, Cat. #I-0634) in the presence of BD GolgiStop ™ (2 µM final concentration Cat. No. 554724). The cells were then fixed, permeabilized, and subsequently stained with 0.06 µg of PE Mouse anti rat IL-10 antibody (PE-A5-4, Cat. No. 555088; Left panel) by using Pharmingen's staining protocol. To demonstrate specificity of staining, the binding of the PE-A5-4 antibody was blocked by preincubation of the PE- conjugated antibody with recombinant rat IL-10 (0.25 µg, Cat. No. 555113; Second panel), and by preincubation of the fixed/permeabilized cells with the unlabeled A5-4 antibody (10 µg; Right panel) prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (Center panel) and unlabeled antibody blocking (Right panel) specificity controls.
本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/kangti/9808.html